Search results for "Lewy Bodies"

showing 10 items of 21 documents

Neurodegeneration in tauopathies and synucleinopathies.

2016

International audience; While increasing life expectancy is a major achievement, the global aging of societies raises a number of medical issues, such as the development of age-related disorders, including neurodegenerative diseases. The three main disease groups constituting the majority of neurodegenerative diseases are tauopathies, alpha-synucleinopathies and diseases due to repetitions of glutamine (including Huntington's disease). In each neurodegenerative disease, the accumulation of one or more aggregated proteins has been identified as the molecular signature of the disease (as seen, for example, in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, amyotrophic lat…

0301 basic medicineLewy Body DiseaseParkinson's disease[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyParkinson's diseaseDementia with Lewy bodiesMédecine humaine et pathologieDiseaseBioinformatics03 medical and health scienceschemistry.chemical_compound0302 clinical medicineParkinsonian Disorders[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineDementiaHumansCytoskeletonSynucleinopathiesAlpha-synucleinInclusion Bodiesbusiness.industryDementia with Lewy bodiesNeurodegenerative diseasesNeurodegenerationassociationBrainNeurodegenerative DiseasesAlzheimer's diseasemedicine.disease3. Good health030104 developmental biologyNeurologychemistryTauopathies[ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyNerve Degenerationalpha-SynucleinDementiapathologyNeurology (clinical)businessNeuroscience030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFrontotemporal dementiadementiaRevue neurologique
researchProduct

The predictive power of transcranial sonography in movement disorders: a longitudinal cohort study.

2018

Transcranial sonography (TCS) is a noninvasive, easily performed, and commonly available neuroimaging technique useful for the study of brain parenchyma in movement disorders. This tool has been increasingly used in the diagnosis of Parkinson’s disease and atypical parkinsonism. The aim of the study was to evaluate the applicability of this technique as supportive tool in the early diagnosis of movement disorders. We performed TCS on 315 individuals which were diagnosed as healthy controls or affected by idiopathic Parkinson’s disease, monogenetic subtypes of Parkinson’s disease, atypical parkinsonism, and Dementia with Lewy bodies. Five TCS diagnostic patterns were defined on the basis of …

0301 basic medicineMalemedicine.medical_specialtyMovement disordersNeurologyUltrasonography Doppler TranscranialConcordanceDementia with Lewy bodiesDermatologyDiseaseCohort Studies03 medical and health sciences0302 clinical medicineNeuroimagingPredictive Value of TestsInternal medicineSubstantia nigramedicineLenticular nucleiHumansNeuroradiologyAgedMovement DisordersDementia with Lewy bodiesbusiness.industryfungiGeneral MedicineMiddle Agedmedicine.diseasePsychiatry and Mental health030104 developmental biologyAtypical parkinsonismIdiopathic Parkinson’s diseaseTranscranial sonographySettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerymedicine.symptombusiness030217 neurology & neurosurgeryNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

The Pharmacology of Visual Hallucinations in Synucleinopathies

2019

Visual hallucinations (VH) are commonly found in the course of synucleinopathies like Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these conditions is so high that the absence of VH in the course of the disease should raise questions about the diagnosis. VH may take the form of early and simple phenomena or appear with late and complex presentations that include hallucinatory production and delusions. VH are an unmet treatment need. The review analyzes the past and recent hypotheses that are related to the underlying mechanisms of VH and then discusses their pharmacological modulation. Recent models for VH have been centered on the role played by the decoupling …

0301 basic medicineParkinson's diseaseParkinson's diseaseReviewPharmacologySerotonergicdefault mode network03 medical and health sciencesGlutamatergic0302 clinical medicineDopaminemedicinePharmacology (medical)Default mode networkPharmacologySynucleinopathiesDementia with Lewy bodiesbusiness.industrylcsh:RM1-950visual hallucinationmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCholinergicSettore MED/26 - Neurologiasynucleinopathydementia with Lewy bodiesbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Modulating disease-relevant tau oligomeric strains by small molecules

2020

The pathological aggregation of tau plays an important role in Alzheimer's disease and many other related neurodegenerative diseases, collectively referred to as tauopathies. Recent evidence has demonstrated that tau oligomers, small and soluble prefibrillar aggregates, are highly toxic due to their strong ability to seed tau misfolding and propagate the pathology seen across different neurodegenerative diseases. We previously showed that novel curcumin derivatives affect preformed tau oligomer aggregation pathways by promoting the formation of more aggregated and nontoxic tau aggregates. To further investigate their therapeutic potential, we have extended our studies o disease-relevant bra…

0301 basic medicinetau oligomeric strainsCurcuminTau proteinsmall moleculetau ProteinsProtein aggregationBiochemistrytau proteinoligomerProgressive supranuclear palsyprotein aggregationDiagnosis DifferentialSmall Molecule Libraries03 medical and health scienceschemistry.chemical_compoundBiopolymersmental disordersmedicineHumansMolecular BiologyCells CulturedNeurons030102 biochemistry & molecular biologybiologyChemistryDementia with Lewy bodiesbrain-derived tau oligomerstau aggregationtauopathytoxicityBrainMolecular Bases of DiseaseCell Biologymedicine.diseaseSmall moleculeImaging agentCell biology030104 developmental biologyTauopathiesbiology.proteinCurcuminTauopathyThe Journal of Biological Chemistry
researchProduct

The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey

2021

IntroductionPrevious studies showed that quarantine for pandemic diseases is associated with several psychological and medical effects. The consequences of quarantine for COVID-19 pandemic in patients with dementia are unknown. We investigated the clinical changes in patients with Alzheimer’s disease and other dementias, and evaluated caregivers’ distress during COVID-19 quarantine.MethodsThe study involved 87 Italian Dementia Centers. Patients with Alzheimer’s Disease (AD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD), and Vascular Dementia (VD) were eligible for the study. Family caregivers of patients with dementia were interviewed by phone in April 2020, 45 days after …

AgingPediatricsmedicine.medical_specialtyCognitive Neurosciencelcsh:RC321-57103 medical and health sciences0302 clinical medicinemental disordersAlzheimer’s disease BPSD caregiver burden COVID-19 dementia quarantinemedicineDementiaBPSD030212 general & internal medicineVascular dementialcsh:Neurosciences. Biological psychiatry. NeuropsychiatryAlzheimer’s disease; BPSD; caregiver burden; COVID-19; dementia; quarantineDepression (differential diagnoses)Original ResearchM-PSI/05 - PSICOLOGIA SOCIALEMED/26 - NEUROLOGIAcaregiver burdenDementia with Lewy bodiesFamily caregiversbusiness.industryquarantineCOVID-19Odds ratiomedicine.diseaseSettore MED/26 - NEUROLOGIADistressMED/17 - MALATTIE INFETTIVEbusinessAlzheimer’s disease030217 neurology & neurosurgeryNeuroscienceFrontotemporal dementiadementia
researchProduct

Protein/lipid coaggregates are formed during α-synuclein-induced disruption of lipid bilayers.

2014

Amyloid formation is associated with neurodegenerative diseases such as Parkinson's disease (PD). Significant α-synuclein (αSN) deposition in lipid-rich Lewy bodies is a hallmark of PD. Nonetheless, an unraveling of the connection between neurodegeneration and amyloid fibrils, including the molecular mechanisms behind potential amyloid-mediated toxic effects, is still missing. Interaction between amyloid aggregates and the lipid cell membrane is expected to play a key role in the disease progress. Here, we present experimental data based on hybrid analysis of two-photon-microscopy, solution small-angle X-ray scattering and circular dichroism data. Data show in real time changes in liposome …

Circular dichroismAmyloidPolymers and PlasticsAmyloidLipid BilayersBioengineeringProtein Structure SecondaryBiomaterialsCell membraneMaterials ChemistrymedicineScattering RadiationLipid bilayerSpectroscopyLiposomeLaurdanAdvanced MicroscopyChemistryCircular DichroismX-RaysNeurodegenerationCell MembraneLipid bilayer fusionProteinsmedicine.diseaseamyloid-membrane interactionco-aggregatemedicine.anatomical_structureMembraneBiophysicsalpha-SynucleinLewy BodiesBiomacromolecules
researchProduct

Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB…

2022

Introduction: Dementia with Lewy bodies (DLB) may represent a diagnostic challenge, since its clinical picture overlaps with other dementia. Two toolkits have been developed to aid the clinician to diagnose DLB: the Lewy Body Composite Risk Score (LBCRS) and the Assessment Toolkit for DLB (AT-DLB). We aim to evaluate the reliability of these two questionnaires, and their ability to enhance the interpretation of the international consensus diagnostic criteria. Methods: LBCRS and AT-DLB were distributed to 135 Italian Neurological Centers for Cognitive Decline and Dementia (CDCDs), with the indication to administer them to all patients with dementia referred within the subsequent 3 months. We…

Lewy Body DiseaseClinical diagnosiDementia with Lewy bodieConsensus criteriaDementia with Lewy bodiesDermatologybehavioral disciplines and activitiesDiagnostic accuracyDiagnosis DifferentialAlzheimer DiseaseDiagnosismental disordersHumansReproducibility of ResultsDiagnostic toolkitGeneral MedicineClinical diagnosis; Cognitive impairment; Consensus criteria; Dementia; Dementia with Lewy bodies; Diagnostic accuracy; Diagnostic toolkitsClinical diagnosisnervous system diseasesSettore MED/26 - NEUROLOGIAPsychiatry and Mental healthCognitive impairmentItalyDifferentialDiagnostic toolkitsDementiaNeurology (clinical)
researchProduct

DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB

2020

Abstract DCTN1 encodes the largest subunit of dynactin complex essential in the retrograde axonal transport and cytoplasmic transport of vesicles; mutations in DCTN1 have been reported predominantly in individuals with Perry syndrome and, recently, in patients with progressive supranuclear palsy. Our genetic screening of DCTN1 in 79 patients with progressive supranuclear palsy, 100 patients with multiple system atrophy, and 28 patients with dementia with Lewy bodies from Italy revealed only synonymous and intronic variants, suggesting that DCTN1 mutations do not have a key role in the development of atypical parkinsonism in the Italian population.

Lewy Body DiseaseMale0301 basic medicineAgingPathologymedicine.medical_specialtyDementia with Lewy bodieDNA Mutational AnalysisDynactinProgressive supranuclear palsy03 medical and health sciences0302 clinical medicineAtrophymedicineHumansIn patientGenetic TestingGenetic Association StudiesAgedDCTN1Dementia with Lewy bodiesbusiness.industryProgressive supranuclear palsyGeneral NeuroscienceParkinson DiseaseDynactin ComplexMiddle AgedMultiple System Atrophymedicine.diseaseDCTN1030104 developmental biologyItalyMutation testingDynactinAxoplasmic transportDCTN1; Dementia with Lewy bodies; Dynactin; Multiple system atrophy; Progressive supranuclear palsyFemaleSupranuclear Palsy ProgressiveNeurology (clinical)Geriatrics and GerontologybusinessNegative Results030217 neurology & neurosurgeryDevelopmental BiologyNeurobiology of Aging
researchProduct

Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: a meta-analysis of longitudinal studies.

2019

Objective: To synthesize the evidence across longitudinal studies comparing survival in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Methods: We conducted a systematic review and meta-analysis of studies comparing survival in clinically diagnosed DLB to AD. Longitudinal cohort studies were identified through a systematic search of major electronic databases from inception to May 2018. A random effects meta-analysis was performed to calculate survival time and relative risk of death. Results: Overall, 11 studies were identified including 22,952 patients with dementia: 2029 with DLB (mean diagnosis age 76.3; 47% female) compared with 20,923 with AD (mean diagnosis age 77.2; 6…

Lewy Body DiseaseMale0301 basic medicineAgingmedicine.medical_specialtyDiseaseBiochemistryLewy bodie03 medical and health sciences0302 clinical medicineA meta-analysis of longitudinal studies.- Ageing research reviews cilt.50 ss.72-80 2019 [MUELLER C. Soysal P. RONGVE A. ISIK A. THOMPSON T. MAGGI S. SMITH L. Basso C. STEWART R. BALLARD C. et al. -Survival time and differences between dementia with Lewy bodies and Alzheimer-s disease following diagnosis]Alzheimer DiseaseInternal medicinemental disordersmedicineHumansDementiaLongitudinal StudiesLongitudinal cohortMortalityMolecular BiologyAgedDementia with Lewy bodiesbusiness.industryCognitive scoreAlzheimer's diseaseRandom effects modelmedicine.diseaseSurvival RateObservational Studies as Topic030104 developmental biologyNeurologyMeta-analysisRelative riskFemaleDementiabusinessLewy bodiesAlzheimer’s disease030217 neurology & neurosurgeryBiotechnology
researchProduct

Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types.

2008

Objective:  i) to describe the neuropsychiatric profile of elderly subjects with dementia by comparing vascular (VaD) and degenerative dementias, i.e. dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD); ii) to assess whether the severity and type of dementia are associated with clinically relevant neuropsychiatric symptoms (CR-NPS). Method:  One hundred and thirty-one out-patients with VaD, 100 with DLB and 690 with AD were studied. NPS were evaluated by the neuropsychiatric inventory (NPI). Results:  Vascular dementia had lower total and domain-specific NPI scores and a lower frequency of CR-NPS than AD and DLB, for which frequency of CR-NPS increased significantly with disease s…

Lewy Body DiseaseMalemedicine.medical_specialtyPathologyPsychometricsDiseaseNeuropsychological TestsCentral nervous system diseaseDegenerative diseaseAlzheimer DiseaseInternal medicinemental disordersmedicineDementiaHumansVascular dementiaAgedAged 80 and overLewy bodyDementia with Lewy bodiesDementia Vasculartechnology industry and agricultureReproducibility of Resultsneuropsychiatric symptoms vascular dementia dementia with Lewy bodies Alzheimer’s disease dementia severitymedicine.diseasePsychiatry and Mental healthnervous systemDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer's diseasePsychologyActa psychiatrica Scandinavica
researchProduct